{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:02:50Z","timestamp":1785765770682,"version":"3.56.0"},"reference-count":66,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Human Vaccines & Immunotherapeutics"],"published-print":{"date-parts":[[2015,1,1]]},"DOI":"10.4161\/hv.35858","type":"journal-article","created":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T20:15:42Z","timestamp":1414872942000},"page":"150-155","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":28,"title":["Adult vaccination"],"prefix":"10.1080","volume":"11","author":[{"given":"Kena A","family":"Swanson","sequence":"first","affiliation":[{"name":"Pfizer Vaccine Research and Early Development; Pearl River, NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H Josef","family":"Schmitt","sequence":"additional","affiliation":[{"name":"Pfizer Vaccines Europe; Paris Cedex, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin U","family":"Jansen","sequence":"additional","affiliation":[{"name":"Pfizer Vaccine Research and Early Development; Pearl River, NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annaliesa S","family":"Anderson","sequence":"additional","affiliation":[{"name":"Pfizer Vaccine Research and Early Development; Pearl River, NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2014,11,1]]},"reference":[{"key":"e_1_3_4_2_1","first-page":"352","article-title":"Benefits from immunization during the vaccines for children program era - United States, 1994-2013","volume":"63","author":"Whitney CG","year":"2014","unstructured":"WhitneyCG, ZhouF, SingletonJ, SchuchatA, Centers for Disease Control and Prevention (CDC). Benefits from immunization during the vaccines for children program era - United States, 1994-2013. MMWR Morb Mortal Wkly Rep2014; 63:352 - 5; PMID: 24759657","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_3_4_3_1","unstructured":"The 2009 Ageing Report: economic and budgetary projections for the EU-27 Member States (2008-2060) Luxembourg: Joint Report prepared by the European Commission (DG ECFIN) and the Economic Policy Committee (AWG).. 2009"},{"key":"e_1_3_4_4_1","unstructured":"BureauUC. . Population by Age and Sex for the United States: 1900 to 2000. PartACensus 2000 Special Reports Series CENSR-4: US Administration on Aging. 2002"},{"key":"e_1_3_4_5_1","unstructured":"US Census Bureau PD. Projections of the Population by Age and Sex for the United States: 2010 to 2050. US Census Bureau Population Division 2008."},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e31824de9f6"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.10.032"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1086\/431521"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2012.02.017"},{"key":"e_1_3_4_10_1","first-page":"110","article-title":"Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older - United States, 2014","volume":"63","author":"Bridges CB","year":"2014","unstructured":"BridgesCB, Coyne-BeasleyT, Advisory Committee on Immunization Practices (ACIP), ACIP Adult Immunization Work Group, Centers for Disease Control and Prevention (CDC). Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older - United States, 2014. MMWR Morb Mortal Wkly Rep2014; 63:110 - 2; PMID: 24500291","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.09.076"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.4161\/hv.8.1.17957"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.080734"},{"key":"e_1_3_4_14_1","first-page":"CD000422","article-title":"Vaccines for preventing pneumococcal infection in adults","volume":"1","author":"Moberley S","year":"2013","unstructured":"MoberleyS, HoldenJ, TathamDP, AndrewsRM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev2013; 1:CD000422; PMID: 23440780","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1023\/B:EJEP.0000024701.94769.98"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.09.019"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02377-1"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis212"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(03)00521-8"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1586\/erv.11.99"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis359"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1086\/503805"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.16.2043"},{"key":"e_1_3_4_24_1","doi-asserted-by":"crossref","unstructured":"M. Bonten MB. S. Huijts C. Webber S. Gault W. Gruber D. Grobbee. Community Acquired Pneumonia Immunisation Trial in Adults (CAPITA). ISPPD. Hyperabad India 2014.","DOI":"10.1093\/ofid\/ofu051.62"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit506"},{"key":"e_1_3_4_26_1","unstructured":"Grijalva CG Wunderink RG Williams D Zhu Y Balk R Fakhran S Courtney M Anderson E Qi C Hicks L et al. Distribution of Pneumococcal Serotypes Detected Through Urine Analysis Among US Adults Hospitalized with Pneumonia After Introduction of PCV13. ISPPD. Hyperabad India 2014."},{"key":"e_1_3_4_27_1","first-page":"Doc12","article-title":"One-day point prevalence of emerging bacterial pathogens in a nationwide sample of 62 German hospitals in 2012 and comparison with the results of the one-day point prevalence of 2010","volume":"8","author":"Wegner C","year":"2013","unstructured":"WegnerC, H\u00fcbnerNO, GleichS, ThalmaierU, Kr\u00fcgerCM, KramerA. One-day point prevalence of emerging bacterial pathogens in a nationwide sample of 62 German hospitals in 2012 and comparison with the results of the one-day point prevalence of 2010. [8:Doc12]GMS Hyg Infect Control2013; 8:Doc12; PMID: 23967398","journal-title":"GMS Hyg Infect Control"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.2217\/fmb.13.65"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.01.056"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.04.002"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1099\/mic.0.066712-0"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199808203390806"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid1512.081341"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid1312.070629"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1086\/501997"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro2164"},{"key":"e_1_3_4_37_1","first-page":"1","article-title":"Clostridium difficile and the microbiota","author":"Seekatz AM","year":"2014","unstructured":"SeekatzAM, YoungVB. Clostridium difficile and the microbiota. J Clin Invest2014; 1 - 8; PMID: 25036699","journal-title":"J Clin Invest"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2006.09.001"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/jhm.1916"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1086\/502522"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2011.01.007"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.4161\/hv.21872"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1586\/erv.11.54"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.3010"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011297"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00451-10"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.01050-13"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0606863103"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.4161\/hv.23223"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00354-12"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00556-07"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis463"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.01576-14"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0074718"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature09397"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.4161\/hv.28428"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.69.2.988-995.2001"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.01.065"},{"key":"e_1_3_4_59_1","unstructured":"Valneva. . An Open-label Study Assessing Safety Immunogenicity and Dose Response of IC84 NCT01296386ClinicalTrialsgov. 2014"},{"key":"e_1_3_4_60_1","unstructured":"Pfizer. Evaluation of a 3-dose Vaccination Regimen With One of Three Ascending Dose Levels of Clostridium Difficile Vaccine With or Without Adjuvant in Healthy Adults Aged 50 to 85 Years NCT01706367. ClinicalTrialsgov. 2014;"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2009.04.001"},{"key":"e_1_3_4_62_1","first-page":"1","article-title":"Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010","volume":"59","author":"Fiore AE","year":"2010","unstructured":"FioreAE, UyekiTM, BroderK, FinelliL, EulerGL, SingletonJA, IskanderJK, WortleyPM, ShayDK, BreseeJS, et al, Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep2010; 59:RR-81 - 62; PMID: 20689501","journal-title":"MMWR Recomm Rep"},{"key":"e_1_3_4_63_1","first-page":"95","article-title":"Noninfluenza vaccination coverage among adults - United States, 2012","volume":"63","author":"Williams WW","year":"2014","unstructured":"WilliamsWW, LuPJ, O\u2019HalloranA, BridgesCB, PilishviliT, HalesCM, MarkowitzLE, Centers for Disease Control and Prevention (CDC). Noninfluenza vaccination coverage among adults - United States, 2012. MMWR Morb Mortal Wkly Rep2014; 63:95 - 102; PMID: 24500288","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051016"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis638"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.06.012"},{"key":"e_1_3_4_67_1","unstructured":"Boutriau D. Evaluation of an investigational 4-componant Staphylococcus aureus vaccine with or without AS03B adjuvant in healthy adults: results from a phase 1 trial. International Symposium on Staphylococci and Staphylococcal Infections Chicago USA August 26-29 1014"}],"container-title":["Human Vaccines & Immunotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.4161\/hv.35858","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.4161\/hv.35858","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.4161\/hv.35858","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T13:39:14Z","timestamp":1785764354000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.4161\/hv.35858"}},"subtitle":["Current recommendations and future prospects"],"short-title":[],"issued":{"date-parts":[[2014,11,1]]},"references-count":66,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1,1]]}},"alternative-id":["10.4161\/hv.35858"],"URL":"https:\/\/doi.org\/10.4161\/hv.35858","relation":{},"ISSN":["2164-5515","2164-554X"],"issn-type":[{"value":"2164-5515","type":"print"},{"value":"2164-554X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,1]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2014-08-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-08-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-11-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}